Last reviewed · How we verify
Boostrix Polio™ 711866
Boostrix Polio is a combined vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and poliovirus.
Boostrix Polio is a combined vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and poliovirus. Used for Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults.
At a glance
| Generic name | Boostrix Polio™ 711866 |
|---|---|
| Also known as | dTpa-IPV |
| Sponsor | GlaxoSmithKline |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This is an inactivated vaccine containing antigens from Corynebacterium diphtheriae toxoid, Clostridium tetani toxoid, Bordetella pertussis (acellular), and inactivated poliovirus types 1, 2, and 3. Upon intramuscular injection, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells against these four pathogens.
Approved indications
- Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults
Common side effects
- Injection site pain
- Injection site redness
- Injection site swelling
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine (PHASE4)
- Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |